Tranexamic Acid Linked to Less Drainage After Immediate ELD Flap Breast Reconstruction

Immediate breast reconstruction after cancer surgery places a premium on hemostasis. In the setting of an extended latissimus dorsi flap reconstruction, even modest postoperative oozing can prolong drain dependence, increase nursing burden, and delay discharge. A retrospective cohort study from two Chinese investigators now adds to the surgical discussion around whether a single intraoperative dose of intravenous tranexamic acid can meaningfully reduce that postoperative fluid burden.

The analysis covered 82 patients who underwent immediate extended latissimus dorsi flap breast reconstruction between January 2019 and May 2026. Forty-two patients received 1 g of intravenous TXA at the start of surgery after routine adoption of the drug in July 2021, while 40 earlier patients underwent the same operation without TXA. Because the groups were separated by time rather than random assignment, the comparison reflects real-world practice rather than a controlled trial. Even so, the signal on postoperative drainage was consistent across the adjusted analyses.

Drain Output and Tube Removal Shifted in the TXA Era

After adjustment for potential confounders, TXA use was associated with a shorter drain duration by 1.85 days, with a 95% confidence interval from 3.09 fewer days to 0.61 fewer days and a p value of 0.004. Total drainage volume fell by 131.5 mL after adjustment, with a 95% confidence interval from 247.2 mL lower to 15.8 mL lower and a p value of 0.027. A complementary Cox model pointed in the same direction: drain removal occurred earlier in the TXA group, with a hazard ratio of 2.59 and a 95% confidence interval of 1.50 to 4.46; the p value was below 0.001.

Those findings matter because drain removal is one of the most tangible postoperative milestones in breast reconstruction. A shorter period of active drainage can reduce patient discomfort, simplify wound care, and limit the cascade of small complications that follow persistent serous output. In a flap-based breast reconstruction, the surgeon is balancing dead space, tissue dissection, and the microvascular consequences of surgery; any intervention that stabilizes the wound bed without impairing flap viability deserves careful attention.

The biologic rationale is straightforward. TXA inhibits fibrinolysis by blocking the interaction between plasminogen and fibrin, helping clot stability at the surgical site. In a wide soft-tissue dissection such as an extended latissimus dorsi flap, that mechanism can plausibly reduce diffuse capillary bleeding and postoperative seepage, especially in the early hours after surgery when the raw surfaces are still sealing.

Hematoma Was Less Frequent, But the Signal Remains Descriptive

The most striking safety-related difference involved hematoma. No hematomas occurred in the TXA group, compared with 6 in the control group, and the between-group comparison reached a p value of 0.011. The investigators explicitly frame this as descriptive and hypothesis-generating rather than definitive. That caution is appropriate: a small cohort, a nonrandomized design, and a time-separated treatment strategy all limit how far one can push a complication comparison.

Even so, the direction of the signal matches the hemostatic mechanism. Hematoma after breast reconstruction is more than a cosmetic issue. It can threaten flap contour, increase pain, trigger reoperation, and complicate donor-site recovery. A medication that lowers blood loss and postoperative fluid accumulation may therefore affect not only the drain clock but also the complication profile that follows a major reconstructive operation.

The study also assessed perioperative hemoglobin, hematocrit, and C-reactive protein, along with postoperative complications, using multivariable linear regression and Cox regression. The abstract does not provide those additional laboratory results in detail, so the central interpretive weight falls on the drainage and hematoma endpoints. Even with that limitation, the pattern is internally coherent: less postoperative fluid, earlier drain removal, and fewer observed hematomas in the TXA-exposed cohort.

What This Means for Breast Reconstruction Practice

This preprint sits squarely in the field of reconstructive surgery, where incremental changes in operative technique can have a large effect on recovery. A single 1 g intravenous dose at the start of the case is operationally simple, inexpensive relative to many perioperative interventions, and easy to incorporate into established workflows. The practical appeal is obvious, especially in procedures where seroma and prolonged drainage are common concerns.

Yet the study design leaves important questions unanswered. Because TXA adoption began in July 2021, the two cohorts were separated by era, and any time-related changes in surgical technique, perioperative management, or postoperative care could influence outcomes. The abstract does not describe flap loss, thromboembolic events, or longer-term reconstructive success in detail. Without randomization, it is impossible to know how much of the observed benefit came from the drug itself versus changes in perioperative practice over time.

The ethical framework was in place, with approval from the Ethics Committee of Nanjing Drum Tower Hospital under approval number 2026-1069-01. The work is also explicitly identified as a preprint, meaning it has not undergone peer review. For now, the most defensible reading is narrow: intravenous TXA was associated with less drainage and fewer hematomas in this immediate breast reconstruction cohort, but prospective randomized studies are still needed before the drug’s exact role can be defined with confidence.

In reconstructive surgery, small reductions in postoperative drainage can translate into faster recovery at the bedside. This cohort suggests that TXA may help achieve that goal, but it also leaves unresolved the central safety question: whether the same hemostatic advantage can be preserved across broader patient groups and with long-term follow-up of reconstructive outcomes.


Reporting by Dr. Aishwarya N., MBBS for Medicine World Foundation, with additional data provided by medRxiv (Clinical Preprints).
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA